Senseera
Company Details
About: Senseera's GEM (Genomic Expression Maps) BIOMARKERS, is a novel biomarker discovery platform based on a patent protected chromatin epigenomics (cfChIP-seq) liquid biopsy technology (Sadeh, Nature Biotechnology, 2021).
GEM BIOMARKERS turns a simple blood draw into unparalleled, quantitative, cell-specific gene expression, and regulation data from cell-free DNA. Going beyond traditional methods like cfDNA genomics and methylation, it offers a transformative layer of data for various applications including biomarker discovery, tissue-agnostic MRD detection, response to therapy, dose optimization, disease subtyping and more.
Backed by a database of over 20,000 annotated disease samples and a 2,000+ healthy subjects cohort, Senseera is collaborating with leading drug developers from big pharma and biotechs, to deliver mechanistic insights with exceptional sensitivity and specificity across multiple indications, advancing human health and precision medicine worldwide.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Senseera | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.